Thyroid Eye Disease (TED) Clinical Trials

thyroid eye disease TED clinical trial tourmaline
Viridian Clinical Trial
forward clinical trial
immunovant clinical studies for thyroid eye disease, TED

amgen rare disease logo
RECRUITING: A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease.
https://clinicaltrials.gov/study/NCT06248619?term=NCT06248619&rank=1

TEPEZZA® (teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease (TED). The first international approval outside of the U.S.

FDA expands teprotumumab indication to include any thyroid eye disease duration, activity.

Research presented  at the American Society of Ophthalmic, Plastic, and Reconstructive Surgery annual meeting noted a decrease in eye muscle size for patients with TED who underwent treatment with TEPEZZA (TM), resulting in better eye movement and less double vision.

sling therapeutics

Sling Therapeutics is now recruiting participants for a Phase 2b study to evaluate a new oral treatment for TED.

divider

immunovant solutions for thyroid eye disease

Immunovant is presently recruiting for a TED clinical research study. Please use this link to learn more.

See “Understanding Thyroid Eye Disease” contributed by Immunovant.

viridian therapeutics

    • VRDN-003-303
    • VRDN-003-304
      • A randomized, open-label study to determine if the investigational drug VRDN-003 for people with active or chronic TED is safe and tolerable and to see how the body reacts when given through a subcutaneous injection using either an autoinjector or a vial and syringe
      • https://clinicaltrials.gov/study/NCT07155668
      • Recruiting participants

Randomized, double-masked, placebo-controlled study to investigate the efficacy and safety of TOUR006 (pacibekitug) in adults with TED

Intervention:
TOUR006 (pacibekitug), a fully human monoclonal antibody against IL-6L
Delivery – subcutaneous injection

Total Number of injections – 3
Time between injections – 8 weeks

Recruiting – 81 participants
NCT Number: NCT06088979
Study Name: spiriTED

Visit: https://clinicaltrials.gov/study/NCT06088979 for more information.